Last reviewed · How we verify
VRVg 1
At a glance
| Generic name | VRVg 1 |
|---|---|
| Sponsor | Sanofi Pasteur, a Sanofi Company |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Study of Purified Vero Rabies Vaccine Compared With a Reference Rabies Vaccine as Simulated Rabies Post-Exposure Prophylaxis in Adult and Pediatric Population in Thaïland (PHASE3)
- Study of Purified Vero Rabies Vaccine Compared With a Reference Rabies Vaccine as Simulated Rabies Post-Exposure Prophylaxis in Adults in Thaïland (PHASE3)
- Immunogenicity and Safety of a Purified Vero Rabies Vaccine (PHASE2)
- Study of the Purified Vero Rabies Vaccine - Serum Free in Comparison With the Reference Purified Vero Rabies Vaccine (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- VRVg 1 CI brief — competitive landscape report
- VRVg 1 updates RSS · CI watch RSS
- Sanofi Pasteur, a Sanofi Company portfolio CI